CD20 Cell Expression Evaluation, Varies
Use
The test is useful for detecting cell-surface antigens on malignant cells that are potential targets for therapeutic antibodies, specifically CD20. It is used to determine patient eligibility for monoclonal antibody therapies and monitor response to these therapies. Monoclonal antibodies like Anti-CD20 are critical therapeutic agents in certain hematologic diseases such as B-cell lymphomas and multiple myeloma.
Special Instructions
This test should not be used as a shortened diagnostic panel. For a comprehensive diagnostic B-cell, T-cell or acute immunophenotyping panel, order LCMS / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies. It is necessary to document expression of markers on malignant cells before starting therapy. Submission of required therapeutic antibody usage and pertinent hematologic diseases information is critical.
Limitations
A complete diagnostic B-cell, T-cell, or acute immunophenotyping panel is not performed, and in some cases, only limited morphologic evaluation is done. This test evaluates CD20 expression only, and is not suitable for assessing other cellular antigens without ordering the respective specific tests.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 100992-7
- 22637-3
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
3 mL
Container
Yellow top (ACD solution A or B), Lavender top (EDTA), Green top (sodium heparin)
Collection Instructions
Label specimen as blood. Send whole blood specimen in original tube. Do not aliquot.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |